These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 25763934)
21. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237 [TBL] [Abstract][Full Text] [Related]
22. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities. Hill RJ; Lou Y; Tan SL Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341 [TBL] [Abstract][Full Text] [Related]
23. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Robak P; Robak T Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347 [TBL] [Abstract][Full Text] [Related]
24. Signal transduction inhibitors in chronic lymphocytic leukemia. Ma S; Rosen ST Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084 [TBL] [Abstract][Full Text] [Related]
25. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Kienle DL; Stilgenbauer S Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560 [TBL] [Abstract][Full Text] [Related]
27. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Thijssen R; Ter Burg J; van Bochove GG; de Rooij MF; Kuil A; Jansen MH; Kuijpers TW; Baars JW; Virone-Oddos A; Spaargaren M; Egile C; van Oers MH; Eldering E; Kersten MJ; Kater AP Leukemia; 2016 Feb; 30(2):337-45. PubMed ID: 26338274 [TBL] [Abstract][Full Text] [Related]
28. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773 [TBL] [Abstract][Full Text] [Related]
29. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Burger JA; Okkenhaug K Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682 [TBL] [Abstract][Full Text] [Related]
30. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow. Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593 [TBL] [Abstract][Full Text] [Related]
31. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Davies A Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890 [TBL] [Abstract][Full Text] [Related]
32. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Crassini K; Shen Y; O'Dwyer M; O'Neill M; Christopherson R; Mulligan S; Best OG Br J Haematol; 2018 Sep; 182(5):654-669. PubMed ID: 29978459 [TBL] [Abstract][Full Text] [Related]